Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
Authors
Keywords
Sulbactam, Breast cancer, ABC transporters, Doxorubicin, Proteomics, Inhibitors
Journal
Cancer Cell International
Volume 18, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-04
DOI
10.1186/s12935-018-0625-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
- (2016) Ann-Marie Meredith et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance
- (2016) Sai A. Balaji et al. PLoS One
- Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
- (2015) William F. Penwell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling
- (2015) Guanqun Ge et al. TUMOR BIOLOGY
- The Global Burden of Cancer 2013
- (2015) Christina Fitzmaurice et al. JAMA Oncology
- Importance of ABCC1 for cancer therapy and prognosis
- (2014) Tereza Kunická et al. DRUG METABOLISM REVIEWS
- Bactericidal effect of sulbactam against Acinetobacter baumannii ATCC 19606 studied by 2D-DIGE and mass spectrometry
- (2014) Cheng-hao Lin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Structural diversity of ABC transporters
- (2014) Josy ter Beek et al. JOURNAL OF GENERAL PHYSIOLOGY
- Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells
- (2013) P Liu et al. BRITISH JOURNAL OF CANCER
- Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients
- (2013) Syamhanin Adnan et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The expression profile of ATP-binding cassette transporter genes in breast carcinoma
- (2013) Viktor Hlaváč et al. PHARMACOGENOMICS
- Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
- (2013) Baoxu Pang et al. Nature Communications
- Early Insights into the Interactions of Different β-Lactam Antibiotics and β-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3
- (2012) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
- (2012) Oktay Tacar et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer Model
- (2011) Lili Bao et al. AMERICAN JOURNAL OF PATHOLOGY
- p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance
- (2010) Ji Yeon Yang et al. BMC CANCER
- Mechanisms and consequences of chemotherapy resistance in breast cancer
- (2009) Helen M. Coley EJC SUPPLEMENTS
- ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome
- (2009) Aaron M. Elliott et al. MOLECULAR CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started